Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

GlobeNewswire 9 days ago

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire 11 days ago

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

GlobeNewswire 13 days ago

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 8, 2024

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

GlobeNewswire October 15, 2024

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 4, 2024

Medicenna Announces Results of Annual Meeting of Shareholders

GlobeNewswire September 26, 2024

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

GlobeNewswire September 9, 2024

Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

GlobeNewswire August 27, 2024

Medicenna Strengthens Board of Directors with Appointment of Karim Lalji

GlobeNewswire August 15, 2024

Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy

GlobeNewswire August 1, 2024

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

GlobeNewswire June 27, 2024

Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe

GlobeNewswire June 26, 2024

Medicenna reveals positive results from brain cancer study

Jocelyn Aspa June 3, 2024

Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting

GlobeNewswire June 3, 2024

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

GlobeNewswire May 31, 2024

Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum

GlobeNewswire May 22, 2024

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting

GlobeNewswire May 13, 2024

Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

GlobeNewswire April 30, 2024